Первая клетка. И чего стоит борьба с раком до последнего

Wohlfarth P. et al. Chimeric Antigen Receptor T-Cell Therapy – A Hematological Success Story. Memo. 11, no. 2 (2018): 116–121.

Titov A. et al. The Biological Basis and Clinical Symptoms of CAR-T Therapy-Associated Toxicities. Cell Death & Disease. 9 (2018): article 897.

Fried Sh. et al. Early and Late Hematologic Toxicity Following CD19 CAR-T Cells. Bone Marrow Transplantation, 2019. doi:10.1038/s41409-019-0487-3.

Brudno J. N., Kochenderfer J. N. Chimeric Antigen Receptor T-Cell Therapies for Lymphoma. Nature Reviews Clinical Oncology. 15 (2018): 31–46.

Mahadeo K. M. Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Nature Reviews Clinical Oncology. 16 (2019): 45–63.

Hoos A. Development of Immuno-Oncology Drugs – From CTLA4 to PD1 to the Next Generations. Nature Reviews Drug Discovery. 15, no. 4 (2016): 235–247.

Coulie P. G. et al. Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy. Nature Reviews Cancer. 14, no. 2 (2014): 135–146.

Schmidt Ch. The Struggle to Do No Harm in Clinical Trials: What Lessons Are Being Learnt from Studies That Went Wrong? Nature, December 20, 2017. doi:10.1038/d41586-017-08705-4.

Maude S. L. et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine. 378, no. 5 (2018): 439–448.

Editorial. CAR T-Cell Therapy: Perceived Need Versus Actual Evidence. Lancet Oncology. 19, no. 10 (2018): 1259.

Osorio J. Cancer Immunotherapy Research Round-Up: Highlights from Clinical Trials. Nature, December 20, 2017.

Barreyro L. et al. Chronic Immune Response Dysregulation in MDS Pathogenesis. Blood. 132, no. 15 (2018): 1553–1560.

Almasbak H. et al. CAR T Cell Therapy: A Game Changer in Cancer Treatment. Journal of Immunology Research, 2016. doi:10.1155/2016/5474602.

Sun Sh. et al. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. Journal of Immunology Research, 2018. doi:10.1155/2018/2386187.

Doudna J. A., Sternberg S. H. A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution. Boston: Houghton Mifflin Harcourt, 2017. [Даудна Дж., Стернберг С. Трещина в мироздании. М.: Corpus, 2019.]

Haapaniemi E. et al. CRISPR – Cas9 Genome Editing Induces a p53-Mediated DNA Damage Response. Nature Medicine, 2018. doi:10.1038/s41591-018-0049-z.

Shin H. Y. et al. CRISPR/Cas9 Targeting Events Cause Complex Deletions and Insertions at 17 Sites in the Mouse Genome. Nature Communications. 8 (2017): article 15464.

Kosicki M. et al. Repair of Double-Strand Breaks Induced by CRISPR – Cas9 Leads to Large Deletions and Complex Rearrangements. Nature Biotechnology. 36 (2018): 765–771.

Глава 7. Харви

Weir H. K. et al. The Past, Present, and Future of Cancer Incidence in the United States: 1975 Through 2020. Cancer. 121, no. 11 (2015): 1827–1837.

By the Numbers: NCI Budget Breakdown, FY 2018. doi:10.1158/2159–8290.CD-NB2019–002.

Aparicio S., Caldas C. The Implications of Clonal Genome Evolution for Cancer Medicine. New England Journal of Medicine. 368 (2013): 842–851.

Walter M. J. et al. Clonal Architecture of Secondary Acute Myeloid Leukemia. New England Journal of Medicine. 366 (2012): 1090–1098.

Ruiz C. et al. Advancing a Clinically Relevant Perspective of the Clonal Nature of Cancer. PNAS. 108 (2011): 12054–12059.